{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:17:45Z","timestamp":1791325065804,"version":"4.3.1"},"reference-count":65,"publisher":"American Chemical Society (ACS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioconjugate Chem."],"published-print":{"date-parts":[[2002,9,1]]},"DOI":"10.1021\/bc025535r","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T04:41:08Z","timestamp":1032324068000},"page":"1079-1092","source":"Crossref","is-referenced-by-count":19,"title":["Trifunctional Conjugation Reagents. Reagents That Contain a Biotin and a Radiometal Chelation Moiety for Application to Extracorporeal Affinity Adsorption of Radiolabeled Antibodies"],"prefix":"10.1021","volume":"13","author":[{"given":"D. Scott","family":"Wilbur","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kuan","family":"Chyan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald K.","family":"Hamlin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Kegley","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt E. B.","family":"Sandberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, Mitra Medical Technology, Lund, Sweden, and National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2002,7,13]]},"reference":[{"key":"bc025535rb00001\/bc025535rb00001_1","volume-title":"Spectrophotometric Method for the Determination of a Bifunctional DTPA Ligand in DTPA-Monoclonal Antibody Conjugates. Bioconjugate Chem. 3, 342\u2212345","author":"Pippin C. G.","year":"1992"},{"key":"bc025535rb00002\/bc025535rb00002_1","first-page":"45","volume":"184","author":"Wilchek M.","year":"1990","journal-title":"Methods Enzymol."},{"key":"bc025535rb00003\/bc025535rb00003_1","volume-title":"Immunoassay","author":"Bayer E. A.","year":"1996"},{"key":"bc025535rb00004\/bc025535rb00004_1","volume-title":"The Biotin-(Strept)Avidin System:\u2009 Principles and Applications in Biotechnology. Clin. Chem. 37, 625\u2212636","author":"Diamandis E. P.","year":"1991"},{"key":"bc025535rb00005\/bc025535rb00005_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1050-3862(99)00034-0","volume":"16","author":"Schetters H.","year":"1999","journal-title":"Biomol. Eng"},{"key":"bc025535rb00006\/bc025535rb00006_1","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2675::AID-CNCR45>3.0.CO;2-6","volume-title":"Pretargeting:\u2009 General Principles. Cancer (Suppl.) 80, 2675\u22122680","author":"Goodwin D. A.","year":"1997"},{"key":"bc025535rb00007\/bc025535rb00007_1","volume-title":"Radioimmunotherapy of Cancer","author":"Chinol M.","year":"2000"},{"key":"bc025535rb00008\/bc025535rb00008_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(96)00477-7","volume":"33","author":"Stoldt H. S.","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"bc025535rb00009\/bc025535rb00009_1","volume-title":"Radioimmunotherapy of Cancer","author":"Theodore L. J.","year":"2000"},{"key":"bc025535rb00010\/bc025535rb00010_1","volume-title":"A Comparative Evaluation of Conventional and Pretargeted Radioimmunotherapy of CD20-Expressing Lymphoma Xenografts. Blood 98, 2535\u22122543","author":"Press O. W.","year":"2001"},{"key":"bc025535rb00011\/bc025535rb00011_1","volume-title":"Proc. Natl. Acad. Sci. U.S.A. 97","author":"Axworthy D. B.","year":"2000"},{"key":"bc025535rb00012\/bc025535rb00012_1","volume-title":"Effect of Endogenous Biotin on the Applications of Streptavidin and Biotin in Mice. Nucl. Med. Biol. 24, 263\u2212268","author":"Rusckowski M.","year":"1997"},{"key":"bc025535rb00013\/bc025535rb00013_1","volume-title":"Quantification and Lowering of Serum Biotin. Lab. Anim. Sci. 45, 554\u2212557","author":"Rosebrough S. F.","year":"1995"},{"key":"bc025535rb00014\/bc025535rb00014_1","first-page":"243","volume-title":"Radioimmunotherapy of Cancer","author":"Strand S.-E.","year":"2000"},{"key":"bc025535rb00015\/bc025535rb00015_1","doi-asserted-by":"crossref","DOI":"10.3109\/02841869609101646","volume":"35","author":"Garkavij M.","year":"1996","journal-title":"Acta Oncol."},{"key":"bc025535rb00016\/bc025535rb00016_1","unstructured":"Garkavij, M. (1996) Improving Radioimmunotargeting of Tumors. The Impact of Extracorporeal Immunoadsorption and Preload in Rats.Doctoral Dissertation, Lund University, Lund, Sweden."},{"key":"bc025535rb00017\/bc025535rb00017_1","volume":"38","author":"Garkavij M.","year":"1997","journal-title":"J. Nucl. Med."},{"key":"bc025535rb00018\/bc025535rb00018_1","volume-title":"Facile Preparation of Nuclease Resistant 3\u2018 Modified Oligodeoxynucleotides. Nucleic Acids Res. 21, 145\u2212150","author":"Gamper H. B.","year":"1993"},{"key":"bc025535rb00019\/bc025535rb00019_1","volume-title":"Antibody fragments in tumor pretargeting. Evaluation of Biotinylated Fab\u2018 Colocalization with Recombinant Streptavidin and Avidin. Bioconjugate Chem. 7, 689\u2212702","author":"Wilbur D. S.","year":"1996"},{"key":"bc025535rb00020\/bc025535rb00020_1","doi-asserted-by":"crossref","unstructured":"Hamblett, K. J., Kegley, B. B., Hamlin, D. K., Chyan, M. K., Hyre, D. E., Press, O. W., Wilbur, D. S., and Stayton, P. S. (2002) A Streptavidin-Binding System that Minimizes Blocking by Endogenous Biotin.Bioconjugate Chem.13, 588\u2212598.","DOI":"10.1021\/bc010087t"},{"key":"bc025535rb00021\/bc025535rb00021_1","volume":"1","author":"Brechbiel M. W.","year":"1992","journal-title":"J. Chem. Soc., Perkin Trans."},{"key":"bc025535rb00022\/bc025535rb00022_1","volume-title":"Biotin Reagents for Antibody Pretargeting. 5. Additional Studies of Biotin Conjugate Design to Provide Biotinidase Stability. Bioconjugate Chem. 12, 616\u2212623","author":"Wilbur D. S.","year":"2001"},{"key":"bc025535rb00023\/bc025535rb00023_1","volume-title":"Streptavidin in Antibody Pretargeting. 2. Evaluation of Methods for Decreasing Localization of Streptavidin to Kidney while Retaining its Tumor Binding Capacity. Bioconjugate Chem. 9, 322\u2212330","author":"Wilbur D. S.","year":"1998"},{"key":"bc025535rb00024\/bc025535rb00024_1","volume-title":"Monoclonal Antibodies to Human Renal Cell Carcinoma:\u2009 Recognition of Shared and Restricted Tissue Antigens. Cancer Res. 45, 6131\u22126139","author":"Vessella R. L.","year":"1985"},{"key":"bc025535rb00025\/bc025535rb00025_1","doi-asserted-by":"crossref","unstructured":"Brown, L., Wegner, S., Wang, H., Buhler, K., Arfman, E., Lange, P., and Vessella, R. (1998) A Novel Monoclonal Antibody 107-1A4 with High Prostate Specificity:\u2009 Generation Characterization of Antigen Expression, and Targeting of Human Prostate Cancer Xenografts.Prostate Cancer Prostatic Dis. 1, 208\u2212215.","DOI":"10.1038\/sj.pcan.4500233"},{"key":"bc025535rb00026\/bc025535rb00026_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1021\/bc00001a007","volume":"1","author":"Mirzadeh S.","year":"1990","journal-title":"Bioconjugate Chem."},{"key":"bc025535rb00027\/bc025535rb00027_1","doi-asserted-by":"crossref","DOI":"10.1385\/089603268X","volume-title":"Basic Protein and Peptide Protocols","author":"Walker J. M.","year":"1994"},{"key":"bc025535rb00028\/bc025535rb00028_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1042\/bj0940023C","volume":"94","author":"Green N. M.","year":"1965","journal-title":"Biochem. J."},{"key":"bc025535rb00029\/bc025535rb00029_1","first-page":"40","volume":"43","author":"Pispa J.","year":"1965","journal-title":"Ann. Med. Exptl. Bio. Fenniae"},{"key":"bc025535rb00030\/bc025535rb00030_1","volume-title":"Biotinidase in Serum and Tissues. Methods Enzymol. 279, 422\u2212434","author":"Hymes J.","year":"1997"},{"key":"bc025535rb00031\/bc025535rb00031_1","volume-title":"Radioimmunoscintigraphy and Radioimmunotherapy of Renal Cell Carcinoma Xenografts. NCI Monogr. 3, 159\u2212167","author":"Vessella R. L.","year":"1987"},{"key":"bc025535rb00032\/bc025535rb00032_1","first-page":"85","volume":"3","author":"Silver D. A.","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"bc025535rb00033\/bc025535rb00033_1","volume-title":"Expression of Potential Target Antigens for Immunotherapy on Primary and Metastatic Prostate Cancers. Clin. Cancer Res. 4, 295\u2212302","author":"Zhang S.","year":"1998"},{"key":"bc025535rb00034\/bc025535rb00034_1","volume":"44","author":"Wilbur D. S.","year":"2001","journal-title":"J. Labeled Cpd. Radiopharm."},{"key":"bc025535rb00035\/bc025535rb00035_1","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.med.52.1.125","volume":"52","author":"White C. A.","year":"2001","journal-title":"Annu. Rev. Med."},{"key":"bc025535rb00036\/bc025535rb00036_1","volume-title":"Encyclopedia of Cancer","author":"Larson S. M."},{"key":"bc025535rb00037\/bc025535rb00037_1","doi-asserted-by":"crossref","DOI":"10.3109\/02841869609101639","volume":"35","author":"Stigbrand T.","year":"1996","journal-title":"Acta Oncol."},{"key":"bc025535rb00038\/bc025535rb00038_1","volume":"35","author":"Kairemo K. J. A.","year":"1996","journal-title":"Acta Oncol."},{"key":"bc025535rb00039\/bc025535rb00039_1","doi-asserted-by":"crossref","unstructured":"Tennvall, J., Garkavij, M., Chen, J., Sjogren, H. O., and Strand, S. E. (1997) Improving Tumor-to-Normal-Tissue Ratios of Antibodies by Extracorporeal Immunoadsorption Based on the Avidin-Biotin Concept:\u2009 Development of a New Treatment Strategy Applied to Monoclonal Antibodies Murine L6 and Chimeric BR96.Cancer 80, 2411\u22122418.","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2411::AID-CNCR12>3.0.CO;2-F"},{"key":"bc025535rb00040\/bc025535rb00040_1","doi-asserted-by":"crossref","DOI":"10.3109\/02841869609101646","volume":"35","author":"Garkavij M.","year":"1996","journal-title":"Acta Oncol."},{"key":"bc025535rb00041\/bc025535rb00041_1","first-page":"133","volume":"29","author":"Green N. M.","year":"1975","journal-title":"Adv. Prot. Chem."},{"key":"bc025535rb00042\/bc025535rb00042_1","volume-title":"Assessment of Biotin Status:\u2009 Clinical Implications. Ann. N. Y. Acad. Sci. 447, 129\u2212132","author":"Baker H.","year":"1985"},{"key":"bc025535rb00043\/bc025535rb00043_1","first-page":"5874S","volume":"55","author":"Garkavij M.","year":"1995","journal-title":"Cancer Res."},{"key":"bc025535rb00044\/bc025535rb00044_1","volume":"38","author":"Garkavij M.","year":"1997","journal-title":"J. Nucl. Med."},{"key":"bc025535rb00045\/bc025535rb00045_1","volume-title":"Ex vivo Biocompatibility of Avidin-Agarose:\u2009 A New Device for Direct Adsorption of Biotinylated Antibodies from Human Whole Blood. Artif. Organs 24, 696\u2212704","author":"Bosch T.","year":"2000"},{"key":"bc025535rb00046\/bc025535rb00046_1","doi-asserted-by":"crossref","unstructured":"Chen, J., Strand, S.E., and Sjoegren, H.O. (1996) Optimization of Radioiodination and Biotinylation of Monoclonal Antibody Chimeric BR96:\u2009 An Indirect Labeling Using N-succinimidyl-3-(tri-n-butylstannyl)benzoate Conjugate.Cancer Biother. Radiopharm. 11, 217\u2212226.","DOI":"10.1089\/cbr.1996.11.217"},{"key":"bc025535rb00047\/bc025535rb00047_1","volume-title":"Biodistribution and Pharmacokinetics of 125I\/131I Pair-Labeled Biotinylated Chimeric BR96 in Colon Carcinoma Isografted Rats. Tumor Targeting 2, 204\u2212214","author":"Chen J.","year":"1996"},{"key":"bc025535rb00048\/bc025535rb00048_1","unstructured":"Garkavij, M., Tennvall, J., Ohlsson, T., Lindgren, L., Hindorf, C., Sjogren, H.O., and Strand, S.E. (1999) Comparison of125I- and111In-Labeled Monoclonal Antibody BR96 for Tumor Targeting in Combination with Extracorporeal Immunoadsorption.Clin. Cancer Res. 5, 3059s\u22123064s."},{"key":"bc025535rb00049\/bc025535rb00049_1","volume":"38","author":"Chen J.","year":"1997","journal-title":"J. Nucl. Med."},{"key":"bc025535rb00050\/bc025535rb00050_1","volume-title":"A Deeply Recessed Active Site in Angiotensin-Converting Enzyme is Indicated From The Binding Characteristics of Biotin-Spacer-Inhibitor Reagents. Biochem Biophys. Res. Commun. 167, 310\u2212316","author":"Bernstein K. E.","year":"1990"},{"key":"bc025535rb00051\/bc025535rb00051_1","doi-asserted-by":"crossref","DOI":"10.1042\/bj2750733","volume":"275","author":"Polli J. W.","year":"1991","journal-title":"Biochem. J."},{"key":"bc025535rb00052\/bc025535rb00052_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/bc9800522","volume":"10","author":"Deguchi Y.","year":"1999","journal-title":"Bioconjugate Chem."},{"key":"bc025535rb00053\/bc025535rb00053_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/1439-7633(20010105)2:1<52::AID-CBIC52>3.0.CO;2-F","volume":"2","author":"Hashimoto M.","year":"2001","journal-title":"ChemBioChem"},{"key":"bc025535rb00054\/bc025535rb00054_1","volume-title":"Vivo Comparison of CHX-DTPA Ligand Isomers in Athymic Mice Bearing Carcinoma Xenografts. Cancer Biother. Radiopharm. 14, 209\u2212220","author":"Roselli M.","year":"1999"},{"key":"bc025535rb00055\/bc025535rb00055_1","volume":"39","author":"Kobayashi H.","year":"1998","journal-title":"J. Nucl. Med."},{"key":"bc025535rb00056\/bc025535rb00056_1","volume-title":"Metal Chelate Stability Studies and Enzyme Digestion of a Peptide-Linked DOTA Derivative and Its Corresponding Radiolabeled Immunoconjugates. Bioconjugate Chem. 4, 275\u2212283.","author":"Li M.","year":"1993"},{"key":"bc025535rb00057\/bc025535rb00057_1","doi-asserted-by":"crossref","unstructured":"Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A Facile, Water-Soluble Method for Modification of Proteins with DOTA. Use of Elevated Temperature and Optimized pH to Achieve High Specific Activity and High Chelate Stability in Radiolabeled Immunoconjugates.Bioconjugate Chem. 5, 565\u2212576.","DOI":"10.1021\/bc00030a012"},{"key":"bc025535rb00058\/bc025535rb00058_1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1749-6632.1985.tb18453.x","volume":"447","author":"Chauhan J.","year":"1985","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"bc025535rb00059\/bc025535rb00059_1","volume-title":"Biotinidase. Methods Enzymol. 184, 103\u2212111","author":"Wolf B.","year":"1990"},{"key":"bc025535rb00060\/bc025535rb00060_1","volume-title":"Isotope Production and Applications in the 21st Century.","author":"Hamlin D. K.","year":"2000"},{"key":"bc025535rb00061\/bc025535rb00061_1","volume-title":"Biotin reagents for antibody pretargeting. 5. Additional Studies of Biotin Conjugate Design to Provide Biotinidase Stability. Bioconjugate Chem. 12, 616\u2212623","author":"Wilbur D. S.","year":"2001"},{"key":"bc025535rb00062\/bc025535rb00062_1","volume-title":"MEDI-031.","author":"Wilbur D. S.","year":"2001"},{"key":"bc025535rn00001\/bc025535rn00001_1","volume-title":"avidin","author":"Abbreviations"},{"key":"bc025535rn00002\/bc025535rn00002_1","volume-title":"Endoradiotherapy"},{"key":"bc025535rn00004\/bc025535rn00004_1","unstructured":"Due to their low water solubility, some of the reagents (i.e.17,18, and NHS-LC-biotin) were dissolved in DMSO prior to addition to the aqueous solutions. It should be noted that the trifunctional reagent8is soluble in water so the 10% aqueous DMSO does not have to be used. Addition of8in 10% aqueous DMSO solution for conjugation with A6H, and additions of17,18and NHS-LC-biotin in neat DMSO for conjugation with 107-1A4, resulted in conjugation solutions that had <3% DMSO by volume."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/bc025535r","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T07:23:49Z","timestamp":1679556229000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/bc025535r"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,13]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,9,1]]}},"alternative-id":["10.1021\/bc025535r"],"URL":"https:\/\/doi.org\/10.1021\/bc025535r","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,13]]}}}